share_log

4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Dogan Meeshanthini

4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Dogan Meeshanthini

4/A:持股變動聲明(修正)-高管 Dogan Meeshanthini
美股SEC公告 ·  10/07 23:33

牛牛AI助理已提取核心訊息

Cardio Diagnostics Holdings, Inc. CEO Dogan Meeshanthini completed a purchase of company stock on September 6, 2024. The transaction involved the acquisition of 68,965 shares of common stock at a price of $0.29 per share. Following this transaction, Meeshanthini's direct holdings in the company increased to a total of 1,655,429 shares. The transaction, characterized as an open market or private purchase, reflects the CEO's direct investment in the company's stock.
Cardio Diagnostics Holdings, Inc. CEO Dogan Meeshanthini completed a purchase of company stock on September 6, 2024. The transaction involved the acquisition of 68,965 shares of common stock at a price of $0.29 per share. Following this transaction, Meeshanthini's direct holdings in the company increased to a total of 1,655,429 shares. The transaction, characterized as an open market or private purchase, reflects the CEO's direct investment in the company's stock.
Cardio Diagnostics Holdings, Inc.首席執行官Dogan Meeshanthini於2024年9月6日完成了對公司股票的購買。 該交易包括以每股0.29美元的價格收購68,965股普通股。 在這筆交易之後,Meeshanthini在公司的直接持股增加到總共1,655,429股。 該交易被描述爲公開市場或私人購買,反映了首席執行官對公司股票的直接投資。
Cardio Diagnostics Holdings, Inc.首席執行官Dogan Meeshanthini於2024年9月6日完成了對公司股票的購買。 該交易包括以每股0.29美元的價格收購68,965股普通股。 在這筆交易之後,Meeshanthini在公司的直接持股增加到總共1,655,429股。 該交易被描述爲公開市場或私人購買,反映了首席執行官對公司股票的直接投資。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。